/ /

  • linkedin
  • Increase Font
  • Sharebar

    Dr. Mali's top 5 predictions in ophthalmology for 2017


    3) The fluocinolone acetonide intravitreal implant will have a breakout year 

    The fluocinolone acetonide intravitreal implant (Iluvien, Alimera Sciences) represents an exciting new class of treatments that I designate as the long-term implant therapy model and appears ready to take off in ophthalmology as a promising treatment modality. As I have described in previous articles, the implant is a nonbiodegradable implant designed to deliver a continuous microdose of fluocinolone acetonide (FAc) to treat diabetic macular edema (DME). This idea of continuous treatment for DME is appealing given the chronic nature of diabetes and the need for sustainability of sufficient levels of medication intraocularly over a prolonged period of time.

    4) Aflibercept utilization will be at the highest levels

    Aflibercept (Eylea, Regneron) has consistently demonstrated excellent efficacy in age-related macular degeneration (AMD), DME, and retinal vein occlusion (RVO) and I expect even more utilization across the board among retinal specialists. For example, based on the 2016 ASRS PAT survey, retinal specialists in the United States would use aflibercept 79.5% of the time in new-onset exudative AMD patients if the cost were the same among all medications.2

    Joshua Mali, MD
    Joshua Mali, MD, is a vitreoretinal surgeon at The Eye Associates, a private multispecialty ophthalmology practice in Sarasota, Florida.

    New Call-to-action


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available


    View Results